Breaking News Instant updates and real-time market news.

SGEN

Seattle Genetics

$67.21

4.35 (6.92%)

08:09
01/09/19
01/09
08:09
01/09/19
08:09

Seattle Genetics announces publication of data from ECHELON-1 Phase 3 trial

Seattle Genetics announced the publication of data from the ECHELON-1 phase 3 clinical trial online in the journal Clinical Cancer Research. The publication, titled "Brentuximab Vedotin Plus Chemotherapy in North American Patients with Newly Diagnosed Stage III or IV Hodgkin Lymphoma," reports data from the North American patient population from ECHELON-1 evaluating ADCETRIS in combination with AVD in newly diagnosed stage III or IV classical Hodgkin lymphoma. These data were previously presented in a poster presentation at the 2018 American Society of Clinical Oncology Annual Meeting. In March 2018, the U.S. Food and Drug Administration approved ADCETRIS in combination with AVD for the treatment of adult patients with previously untreated stage III or IV classical HL based on the positive results of the ECHELON-1 phase 3 clinical trial. ADCETRIS is an antibody-drug conjugate directed to CD30, a defining marker of classical HL that plays a role in tumor growth and survival. Of the 1,334 advanced stage classical HL patients who participated in the ECHELON-1 clinical trial, 497 patients were treated in North America, with 250 patients in the ADCETRIS plus AVD arm and 247 patients in the ABVD control arm. The manuscript presents the North American results which include: A pre-specified sensitivity analysis showed per Independent Review Facility (IRF) assessment, the two-year modified progression-free survival rate for patients in the ADCETRIS plus AVD arm was 84.3 percent compared to 73.7 percent in the control arm, which corresponds to a difference of 10.6 percent. On the ADCETRIS plus AVD arm, peripheral neuropathy events were observed in 80 percent of patients compared to 56 percent on the ABVD arm. In the ADCETRIS plus AVD arm, the majority of peripheral neuropathy events were Grade 1 or 2. Grade 3 events were reported in 17 percent of patients. In the ABVD arm, Grade 3 events were reported in less than one percent of patients. There were no Grade 4 events on either arm. Across both arms of the study, approximately 75 percent of the patients with peripheral neuropathy reported resolution or improvement at last follow-up. Febrile neutropenia during treatment was reported in 20 percent of patients in the ADCETRIS plus AVD arm compared with nine percent in the ABVD arm. In the ADCETRIS plus AVD arm, 14 percent received primary prophylactic G-CSF within five days of starting treatment and nine percent reported febrile neutropenia. Pulmonary toxicity was reported in three percent of patients in the ADCETRIS plus AVD arm versus ten percent of patients in the ABVD arm. Grade greater than or equal to3 events were reported in two percent versus six percent of patients, in the ADCETRIS plus AVD and ABVD arms, respectively.

SGEN Seattle Genetics
$67.21

4.35 (6.92%)

12/04/18
WBLR
12/04/18
NO CHANGE
WBLR
Outperform
Seattle Genetics' T-cell lymphoma data best case scenario, says William Blair
The "quality and robustness" of the data Seattle Genetics reported from the successful Phase III Ecehlon-2 study, which assesses the safety and efficacy of Adcetris plus a three-drug chemotherapy regimen versus the standard of care four-drug chemotherapy regimen in frontline mature T-cell lymphomas, represent the "best case scenario," William Blair analyst Andy Hsieh tells investors in a research note. The analyst highlights that the indication was approved 11 days after Seattle Genetics submitted the regulatory application to the FDA, which took advantage of the Real-Time Oncology Review Program. He believes Adcetris will be "quickly adopted" in the frontline mature T-cell lymphoma setting, a $400M market in the United States alone. The analyst keeps an Outperform rating on the shares.
11/27/18
PIPR
11/27/18
NO CHANGE
Target $66
PIPR
Neutral
Piper gets positive feedback on Seattle Genetics label expansion
Piper Jaffray analyst Joseph Catanzaro conducted two key opinion leader calls to gauge sentiment around the data included in Seattle Genetics' Echelon-2 label expansion of Adcetris into CD30+ front-line T-cell lymphoma. The leaders provided "overwhelmingly positive feedback" specifically for anaplastic large cell lymphoma patients, and dismissed any concerns cited with Echelon-1, Catanzaro tells investors in a research note. The analyst, however, awaits greater clarity on the non-ALCL subgroup analyses at the upcoming American Society of Hematology meeting and reiterates a Neutral rating on Seattle Genetics with a $66 price target.
11/16/18
COWN
11/16/18
NO CHANGE
Target $71
COWN
Market Perform
Seattle Genetics risk/reward favorable ahead of ASH, says Cowen
Cowen analyst Boris Peaker said the risk/reward for Seattle Genetics ahead of the ASH meeting is favorable given the shares' recent selloff. The company announced that ECHELON-2 met its primary endpoint and demonstrated improvement in CR and OS for A+CHP over standard of care CHOP, noted Peaker, who maintained his Market Perform rating and $71 price target on Seattle Genetics shares.
10/26/18
BOFA
10/26/18
DOWNGRADE
Target $55
BOFA
Underperform
Seattle Genetics cut to Underperform at BofA/Merrill on slower Adcetris ramp
As reported earlier, BofA/Merrill analyst Tazeen Ahmad downgraded Seattle Genetics to Underperform from Neutral and lowered his price target to $55 from $72 after its Q3 update on Adcetris yesterday. The analyst notes that the key driver in the rating change is the reset of expectations for the Adcetris ramp, adding that a poll of physicians also indicates that the "current low cost standard of care" in Hodgkin's will remain their first choice among the earlier stage 1-2 patients.

TODAY'S FREE FLY STORIES

BIIB

Biogen

$320.99

-14.02 (-4.18%)

16:39
02/21/19
02/21
16:39
02/21/19
16:39
Downgrade
Biogen rating change  »

Biogen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 28

    May

GMED

Globus Medical

$47.68

0.05 (0.10%)

16:38
02/21/19
02/21
16:38
02/21/19
16:38
Earnings
Globus Medical reports Q4 EPS 43c, consensus 39c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 06

    Mar

CASA

Casa Systems

$11.96

-0.02 (-0.17%)

16:38
02/21/19
02/21
16:38
02/21/19
16:38
Earnings
Casa Systems sees FY19 EPS 30c-40c, consensus 73c »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 13

    Mar

REGN

Regeneron

$418.66

-3.9 (-0.92%)

16:38
02/21/19
02/21
16:38
02/21/19
16:38
Downgrade
Regeneron rating change  »

Regeneron downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 11

    Mar

  • 11

    Mar

  • 28

    Apr

  • 13

    May

MBIN

Merchants Bancorp

$21.92

-0.08 (-0.36%)

16:38
02/21/19
02/21
16:38
02/21/19
16:38
Hot Stocks
Merchants Bancorp raises quarterly dividend 17% to 7c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HF

HFF Inc.

$42.40

-0.26 (-0.61%)

16:38
02/21/19
02/21
16:38
02/21/19
16:38
Earnings
HFF Inc. reports Q4 EPS $1.11, consensus $1.04 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

HASI

Hannon Armstrong

$23.67

0.16 (0.68%)

16:37
02/21/19
02/21
16:37
02/21/19
16:37
Hot Stocks
Hannon Armstrong announces changes on leadership team »

Hannon Armstrong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

SEM

Select Medical

$15.49

-0.11 (-0.71%)

16:37
02/21/19
02/21
16:37
02/21/19
16:37
Earnings
Select Medical backs FY19 EPS view 97c-$1.13, consensus $1.10 »

Backs FY19 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

BOOM

DMC Global

$35.37

0.04 (0.11%)

16:37
02/21/19
02/21
16:37
02/21/19
16:37
Earnings
Breaking Earnings news story on DMC Global »

DMC Global sees Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 28

    Mar

BIDU

Baidu

$171.72

0.64 (0.37%)

16:36
02/21/19
02/21
16:36
02/21/19
16:36
Hot Stocks
Baidu reports Baidu App DAUs reach 161M in December, up 24% y/y »

Baidu App daily active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 20

    Mar

CPB

Campbell Soup

$35.44

0.26 (0.74%)

16:36
02/21/19
02/21
16:36
02/21/19
16:36
Hot Stocks
Campell Soup to sell Campbell Fresh Plant to JGC affiliate »

Campbell Soup announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    May

MGM

MGM Resorts

$28.34

-0.48 (-1.67%)

16:36
02/21/19
02/21
16:36
02/21/19
16:36
Hot Stocks
MGM reaffirms previously announced 2020 free cash flow targets »

MGM Resorts reaffirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

CASA

Casa Systems

$11.96

-0.02 (-0.17%)

16:36
02/21/19
02/21
16:36
02/21/19
16:36
Earnings
Casa Systems reports Q4 EPS 20c, consensus 14c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 13

    Mar

BOOM

DMC Global

$35.37

0.04 (0.11%)

16:36
02/21/19
02/21
16:36
02/21/19
16:36
Earnings
DMC Global reports Q4 EPS 46c, consensus 36c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 28

    Mar

WRB

W. R. Berkley

$82.37

-0.16 (-0.19%)

16:36
02/21/19
02/21
16:36
02/21/19
16:36
Hot Stocks
W. R. Berkley announces 3-for-2 stock split »

W. R. Berkley announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:35
02/21/19
02/21
16:35
02/21/19
16:35
General news
Fed Balance Sheet Level data reported »

Week of 2/20 Fed Balance…

16:35
02/21/19
02/21
16:35
02/21/19
16:35
General news
Money Supply M2 Weekly Change data reported »

Week of 2/11 Money Supply…

16:35
02/21/19
02/21
16:35
02/21/19
16:35
General news
Quarterly Services Report (Advance) Information Revenue data reported »

Quarterly Services Report…

16:35
02/21/19
02/21
16:35
02/21/19
16:35
General news
Quarterly Services Report (Advance) Information Revenue data reported »

Quarterly Services Report…

MGM

MGM Resorts

$28.34

-0.48 (-1.67%)

16:35
02/21/19
02/21
16:35
02/21/19
16:35
Hot Stocks
MGM announces resignation of CFO Dan D'Arrigo, appoints Corey Sanders to role »

MGM Resorts announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

SUNS

Solar Senior Capital

$16.81

0.05 (0.30%)

16:35
02/21/19
02/21
16:35
02/21/19
16:35
Earnings
Solar Senior Capital reports Q4 NII 35c, consensus 35c »

At December 31, 2018, net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

OPNT

Opiant Pharmaceuticals

$14.65

-0.25 (-1.68%)

16:35
02/21/19
02/21
16:35
02/21/19
16:35
Hot Stocks
Breaking Hot Stocks news story on Opiant Pharmaceuticals »

Opiant Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HASI

Hannon Armstrong

$23.67

0.16 (0.68%)

16:34
02/21/19
02/21
16:34
02/21/19
16:34
Hot Stocks
Hannon Armstrong confirms 2018-2020 guidance »

The Company is confirming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

BIDU

Baidu

$171.72

0.64 (0.37%)

16:34
02/21/19
02/21
16:34
02/21/19
16:34
Hot Stocks
Baidu CEO says 'we are excited to enter the new year on strong footing' »

"We are excited to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 20

    Mar

TGH

Textainer

$13.05

-0.06 (-0.46%)

16:34
02/21/19
02/21
16:34
02/21/19
16:34
Earnings
Textainer reports Q4 EPS 21c, consensus 35c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.